Failure to submit a complete BLA for HIV is entire
Post# of 154058
(Total Views: 637)
Posted On: 05/01/2022 12:41:29 PM
Re: Evil Rabbit #122699
Failure to submit a complete BLA for HIV is entirely Pourhassan's fault.
Pourhassan's email exchange with Amarex shows with 100% certainty that Pourhassan knew the BLA was defective and would be rejected.
Pourhassan made the decision to submit a defective BLA and then loudly and publicly lie to the investor community that the BLA was complete and had been submitted.
That horrific decision was entirely Pourhassan's fault.
And that decision is what has almost completely destroyed the Cytodyn share price.
On the bright side, things can't get much worse for Cytodyn shareholders.
Worst case, Cytodyn is recapitalized at around ten to 15 cents per share. A good management team might be able to take the share price 10x or 100x of that value in only a couple years.
Or perhaps the real worst case for investors is if Cytodyn gets taken private at 50 cents per share. That might be the best thing for patients and investors as long as the investors can survive a couple three years of illiquidity.
Cytodyn is trying to execute the secondary sale of 60 million shares.
If the Cytodyn team can get that offering done at 25 cents per share, then the Cytodyn team will have about six months to get the HIV BLA filed.
Pourhassan's email exchange with Amarex shows with 100% certainty that Pourhassan knew the BLA was defective and would be rejected.
Pourhassan made the decision to submit a defective BLA and then loudly and publicly lie to the investor community that the BLA was complete and had been submitted.
That horrific decision was entirely Pourhassan's fault.
And that decision is what has almost completely destroyed the Cytodyn share price.
On the bright side, things can't get much worse for Cytodyn shareholders.
Worst case, Cytodyn is recapitalized at around ten to 15 cents per share. A good management team might be able to take the share price 10x or 100x of that value in only a couple years.
Or perhaps the real worst case for investors is if Cytodyn gets taken private at 50 cents per share. That might be the best thing for patients and investors as long as the investors can survive a couple three years of illiquidity.
Cytodyn is trying to execute the secondary sale of 60 million shares.
If the Cytodyn team can get that offering done at 25 cents per share, then the Cytodyn team will have about six months to get the HIV BLA filed.
(3)
(6)